Roivant Sciences ROIV
Roivant Sciences FY 2024: revenue $29.1M, down 77%; diluted EPS −$0.24
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001140361-25-020715
- Document
- 10-K
- Exhibit 10.34
- Material contract
- Exhibit 10.35
- Material contract
- Exhibit 10.36
- Material contract
- Exhibit 10.37
- Material contract
- Exhibit 10.38
- Material contract
Key figures from this report
These are the numbers Roivant Sciences reported for the year ended Mar 31, 2025, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$29.1M−77% from $124.8M in FY 202310-K income statement, on EDGAR
- Net income−$172.0M−104% from $4.3B in FY 202310-K income statement, on EDGAR
- Diluted EPS−$0.24−105% from $5.23 in FY 202310-K income statement, on EDGAR
- Cash and cash equivalents$2.7B−58% from $6.5B in FY 2023Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$839.5MAgainst −$765.3M in FY 202310-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Neurocrine Biosciences NBIX public float $9.5B, Jun 30, 2025
- Exelixis EXEL public float $9.4B, Jul 4, 2025
- BIO-TECHNE TECH public float $9.1B, Dec 31, 2025
- United Therapeutics UTHR public float $11.2B, Jun 30, 2025
- Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025